Analytical Discovery of Synergistic Cannabinoid Formulations for Dopaminergic Support and Neuroprotection

Tatiana Zvagelsky, R&D, CBX Therapeutics, Beer sheva, Israel (tatiana@cbxtx.com)

The increasing prevalence of neurodegenerative diseases necessitates evidence-based therapeutic development. While cannabinoid interventions show neuroprotective promise, current formulations lack systematic analytical validation, resulting in inconsistent clinical outcomes.

We present CLARIFY™, an analytical discovery platform that systematically characterizes synergistic cannabinoid combinations through integrated bioanalytical methodologies. Our multi-parameter screening workflow employs quantitative cell viability assays, ELISA-based dopamine secretion profiling, and dose-response curve analysis across 10^-9 to 10^-5 M concentration ranges. Fluorescence spectrophotometric detection methods are employed to track and measure biological effects and target engagement. Statistical modeling using response surface methodology identifies synergistic interactions and optimizes component ratios for maximum biological activity.

The optimized lead formulation demonstrated a 5.2-fold enhancement in dopamine release by neuronal cells compared to individual components while maintaining neuronal viability. Analytically precise combinations of cannabinoids further support precise dosing, drug delivery systems for desired pharmacokinetic profiles, and dosage form considerations to facilitate future translational progression.

Our CLARIFY™ bio/analytical framework transforms empirical cannabinoid development into a data-driven process. The platform's systematic approach, starting from initial screening through formulation optimization and culminating in bioactive, ready-for-translation multi-component therapeutic products, presents a paradigm shift in botanical drug discovery. The combination approach amalgamating analytics, disease models, and AI-powered experimental design provides the quantitative foundation necessary for translating botanical therapeutics into clinically viable neuroprotective interventions.

Short Biography of Presenting Author

I am an R&D leader with a proven track record in cannabinoid biology and therapeutic formulation, bridging deep scientific expertise with translational drug development.

At CBX Therapeutics, I lead the rational design and screening of cannabinoid-based neuroprotective combinations. Using advanced mixture-design approaches and mechanistic cellular assays, we identify synergistic leads with strong efficacy in dopamine release and oxidative stress reduction.

What drives me: transforming rigorous research into investable biotech products that contribute to the longevity revolution and change the course of neurodegenerative diseases like Parkinson’s.

Enable GingerCannot connect to Ginger Check your internet connection

or reload the browserDisable Ginger?How to use GingerRephraseRephrase with Ginger (Ctrl+Alt+E)Edit in GingerGinger is checking your text for mistakes...×


Analytical Discovery of Synergistic Cannabinoid Formulations for Dopaminergic Support and Neuroprotection Tatiana Zvagelsky, R&D, CBX Therapeutics, Beer sheva, Israel (tatiana@cbxtx.com) The increasing prevalence of neurodegenerative diseases necessitates evidence-based therapeutic development. While cannabinoid interventions show neuroprotective promise, current formulations lack systematic analytical validation, resulting in inconsistent clinical outcomes. We present CLARIFY™, an analytical discovery platform that systematically characterizes synergistic cannabinoid combinations through integrated bioanalytical methodologies. Our multi-parameter screening workflow employs quantitative cell viability assays, ELISA-based dopamine secretion profiling, and dose-response curve analysis across 10^-9 to 10^-5 M concentration ranges. Fluorescence spectrophotometric detection methods are employed to track and measure biological effects and target engagement. Statistical modeling using response surface methodology identifies synergistic interactions and optimizes component ratios for maximum biological activity. The optimized lead formulation demonstrated a 5.2-fold enhancement in dopamine release by neuronal cells compared to individual components while maintaining neuronal viability. Analytically precise combinations of cannabinoids further support precise dosing, drug delivery systems for desired pharmacokinetic profiles, and dosage form considerations to facilitate future translational progression. Our CLARIFY™ bio/analytical framework transforms empirical cannabinoid development into a data-driven process. The platform's systematic approach, starting from initial screening through formulation optimization and culminating in bioactive, ready-for-translation multi-component therapeutic products, presents a paradigm shift in botanical drug discovery. The combination approach amalgamating analytics, disease models, and AI-powered experimental design provides the quantitative foundation necessary for translating botanical therapeutics into clinically viable neuroprotective interventions. Enable Ginger Cannot connect to Ginger Check your internet connection or reload the browser Disable Ginger ? How to use Ginger Rephrase Rephrase with Ginger (Ctrl+Alt+E) Edit in Ginger Ginger is checking your text for mistakes... × Short Biography of Presenting Author I am an R&D leader with a proven track record in cannabinoid biology and therapeutic formulation, bridging deep scientific expertise with translational drug development. At CBX Therapeutics, I lead the rational design and screening of cannabinoid-based neuroprotective combinations. Using advanced mixture-design approaches and mechanistic cellular assays, we identify synergistic leads with strong efficacy in dopamine release and oxidative stress reduction. What drives me: transforming rigorous research into investable biotech products that contribute to the longevity revolution and change the course of neurodegenerative diseases like Parkinson’s. Enable GingerCannot connect to Ginger Check your internet connection or reload the browserDisable Ginger?How to use GingerRephraseRephrase with Ginger (Ctrl+Alt+E)Edit in GingerGinger is checking your text for mistakes...×

Organized & Produced by:	www.isranalytica.org.il POB 4043, Ness Ziona 70400, Israel Tel.: +972-8-9313070, Fax: +972-8-9313071 Site: www.bioforum.org.il, E-mail: hagit@bioforum.co.il